Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $35.1 million.

  • Eton Pharmaceuticals' Non-Current Assets rose 433.65% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.5 million, marking a year-over-year increase of 433.65%. This contributed to the annual value of $35.1 million for FY2024, which is 616.22% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Non-Current Assets of $35.1 million as of FY2024, which was up 616.22% from $4.9 million recorded in FY2023.
  • Eton Pharmaceuticals' 5-year Non-Current Assets high stood at $35.1 million for FY2024, and its period low was $1.6 million during FY2020.
  • Its 3-year average for Non-Current Assets is $15.0 million, with a median of $5.0 million in 2022.
  • Per our database at Business Quant, Eton Pharmaceuticals' Non-Current Assets dropped by 21.57% in 2020 and then soared by 616.22% in 2024.
  • Eton Pharmaceuticals' Non-Current Assets (Yearly) stood at $1.6 million in 2020, then soared by 138.63% to $3.9 million in 2021, then soared by 30.17% to $5.0 million in 2022, then fell by 2.49% to $4.9 million in 2023, then soared by 616.22% to $35.1 million in 2024.